Chemoprevention with isothiocyanates - From bench to bedside

Gründemann, Carsten and Huber, Roman. (2018) Chemoprevention with isothiocyanates - From bench to bedside. Cancer letters, 414. pp. 26-33.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/75704/

Downloads: Statistics Overview


Isothiocyanates (ITCs) are naturally occurring hydrolization products from glucosinolates (GLSs) in brassicaceae and in epidemiological studies their intake has been weakly to moderately inversely correlated with the risk of colorectal cancer, prostate cancer and lung cancer. Numerous preclinical studies demonstrate chemopreventive mode of actions of ITCs, mainly related to a.) detoxification (induction of phase II enzymes), b.) anti-inflammatory properties by down-regulation of NFkappaB activity, c.) cyclin-mediated cell cycle arrest and d.) epigenetic modulation by inhibition of histone deacetylase activity. First prospective clinical trials were promising in patients with risk of prostate cancer recurrence. The glutathione-S-transferase gene expression seems to play a major role in the individual susceptibility towards ITCs. Safety issues are widely unclear and should be more addressed in future studies because ITCs can, in low concentrations, compromise the function of human immune cells and might impair genome stability.
Faculties and Departments:05 Faculty of Science > Departement Pharmazeutische Wissenschaften > Pharmazie > Translationale Komplementärmedizin (Gründemann)
UniBasel Contributors:Gründemann, Carsten
Item Type:Article, refereed
Article Subtype:Research Article
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:28 Mar 2020 14:37
Deposited On:28 Mar 2020 14:37

Repository Staff Only: item control page